	30-day mortality (n=856)				six-month mortality (n=809)				two-year mortality (n=809)			
	survivor (n=829)		non-survivor (n=27)	p-value	survivor (n=760)		non-survivor (n=49)	p-value	survivor (n=725)		non-survivor (n=84)	p-value
Comorbidity												
NYHA III/IV heart failure (%)	673	(81)	22 (82)	1	616	(81)	41 (84)	0.85	585	(81)	72 (86)	0.26
Coronary artery disease (%)	353	(43)	15 (56)	0.13	322	(42)	28 (57)	0.053	298	(41)	52 (62)	**<0.001**
Pulmonary hypertension (%)	186	(22)	14 (52)	**0.002**	172	(23)	21 (43)	**0.003**	159	(22)	34 (40)	**<0.001**
COPD (%)	61	(7)	3 (11)	0.45	53	(7)	7 (14)	0.08	46	(6)	14 (17)	**0.001**
Status past stroke (%)	30	(04)	3 (11)	0.08	26	(3)	5 (10)	**0.03**	23	(3)	8 (10)	**0.004**
Diabetes (%)	137	(17)	7 (26)	0.20	125	(16)	14 (29)	**0.048**	117	(16)	22 (26)	**0.02**
Medication												
Beta blocker (%)	545	(66)	22 (81)	0.10	502	(66)	38 (78)	0.12	476	(66)	64 (76)	0.05
Diuretic (%)	377	(45)	20 (74)	**0.005**	343	(45)	35 (71)	**<0.001**	317	(44)	61 (73)	**<0.001**
ACE inhibitor (%)	472	(57)	15 (56)	1	429	(57)	30 (61)	0.55	411	(57)	48 (57)	0.94
AT-1 blocker (%)	54	(7)	4 (15)	0.10	52	(7)	4 (8)	0.77	49	(7)	7 (8)	0.59
Calcium antagonist (%)	131	(16)	3 (11)	0.79	122	(16)	7 (14)	0.84	119	(16)	10 (12)	0.29
Acetylsalicylic acid (%)	253	(31)	10 (37)	0.53	231	(30)	18 (37)	0.34	215	(30)	34 (40)	**0.04**
Warfarin (%)	75	(9)	3 (11)	0.73	66	(9)	8 (16)	0.12	63	(9)	11 (13)	0.19
Statin (%)	250	(30)	12 (44)	0.14	231	(30)	19 (39)	0.26	220	(30)	30 (36)	0.31
Amiodarone (%)	18	(2)	2 (7)	0.13	17	(2)	2 (4)	0.32	17	(2)	2 (2)	0.98
Preoperative												
Creatinine (mg/dl)	1.0	(0.9-1.2)	1.3 (1.1-1.7)	**<0.001**	1.0	(0.9-1.2)	1.2 (1.0-1.6)	**<0.001**	1.0	(0.9-1.2)	1.2 (1.0-1.6)	**<0.001**
Gamma-glutamyl transpeptidase (U/l)	36	(24-60)	59 (32-97)	**0.01**	36	(25-58)	57 (29-94)	**0.008**	36	(24-58)	43 (28-93)	**0.013**
Aspartate Aminotransferase (U/l)	27	(23-34)	31 (25-50)	0.06	27	(23-34)	28 (25-45)	0.05	27	(23-34)	28 (23-42)	0.21
Alanine Aminotransferase (U/l)	25	(18-36)	23 (16-43)	0.75	25	(18-36)	22 (16-37)	0.23	25	(18-36)	22 (16-33)	**0.018**
Bilirubin (mg/dl)	0.6	(0.4-0.8)	0.9 (0.5-1.2)	**0.002**	0.6	(0.4-0.8)	0.8 (0.5-1.1)	**0.002**	0.6	(0.4-0.8)	0.6 (0.4-1.0)	0.07
Albumin (g/l)	45	(42-48)	40 (38-44)	**<0.001**	45	(43-48)	41 (35-45)	**<0.001**	46	(43-48)	42 (38-46)	**<0.001**
Quick-value (%)	98	(89-100)	90 (61-100)	**0.008**	98	(89-100)	92 (67-100)	**0.003**	98	(90-100)	93 (76-100)	**0.001**
Hemoglobin (g/dl)	14.0	(12.7-15.1)	12.5 (11.1-13.8)	**0.001**	14.1	(13.0-15.1)	12.4 (11.1-13.9)	**<0.001**	14.1	(13.0-15.1)	12.6 (11.2-14.2)	**<0.001**
Thrombocytes ($x10^9$/l)	224	(186-262)	219 (168-275)	0.53	225	(188-261)	225 (171-309)	0.96	225	(188-262)	226 (167-262)	0.39
Postoperative												
Creatinine (mg/dl)	0.9	(0.7-1.1)	1.3 (1.2-1.7)	**<0.001**	0.9	(0.7-1.1)	1.3 (1.0-1.7)	**<0.001**	0.9	(0.7-1.1)	1.2 (1.0-1.7)	**<0.001**
Bilirubin (mg/dl)	0.8	(0.5-1.1)	2.0 (1.6-3.4)	**<0.001**	0.8	(0.5-1.1)	1.6 (0.9-2.8)	**<0.001**	0.8	(0.5-1.1)	1.2 (0.6-2.1)	**<0.001**
Quick-value (%)	77	(65-85)	54 (41-69)	**<0.001**	77	(65-85)	61 (48-84)	**<0.001**	77	(66-85)	67 (53-85)	**0.002**
Hemoglobin (g/dl)	10.2	(9.5-11.1)	10.0 (9.3-10.7)	0.36	10.2	(9.5-11.1)	10.0 (9.2-10.9)	0.29	10.2	(9.6-11.1)	10.1 (9.3-10.9)	0.13
Thrombocytes ($x10^9$/l)	138	(113-168)	103 (69-141)	**<0.001**	138	(113-168)	115 (88-156)	**0.02**	139	(114-168)	120 (93-156)	**0.003**
Outcome												
Mechanical ventilated (h)	11	(8-17)	79 (31-288)	**<0.001**	10	(8-16)	68 (26-233)	**<0.001**	10	(8-15)	37 (18-154)	**<0.001**
Renal replacement therapy (%)	42	(5)	17 (63)	**<0.001**	25	(3)	29 (59)	**<0.001**	20	(3)	34 (41)	**<0.001**

Length of stay (days)												
In ICU	1	(1-2)	4	(2-12)	**<0.001**	1	(1-1)	4	(2-12)	**<0.001**	1	(1-1)	3	(1-9)	**<0.001**
In hospital	10	(9-13)	11	(7-19)	0.9	10	(9-12)	14	(8-26)	**0.037**	10	(9-12)	13	(9-22)	**0.001**

Supplemental Digital Content 1, Table: Additional population characteristics. Continuous variables are expressed as median and interquartile range. Categorical variables are presented as numbers (percentages). ACE inhibitor (angiotensin-converting-enzyme inhibitor), AT1 blocker (angiotensin II type 1 receptor blocker), COPD (chronic obstructive pulmonary disease), ICU (intensive care unit), NYHA class (New York Heart Association class).